|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Fritsch, EF, Hacohen, N, Wu, CJ|
Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient's tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstanding questions and desired further improvements, neoantigen vaccines are currently undergoing clinical evaluation.